TITLE : "Tissue Eosinophil Counts as Predictors of Infliximab Response in Pediatric Inflammatory Bowel Disease: A Retrospective Nested Case Control Study"

Émile L'Heureux-Hubert[1,2] Samuel Sassine[1,2] Sophia Ferrante[1,2] Natacha Patey[1,2] Prévost Jantchou[1,2]

1 Centre de recherche Azrieli du Centre Hospitalier Universitaire Sainte-Justine

2 Département de Médecine de l'Université de Montréal

ABSTRACT

Background: Infliximab is an effective therapy for pediatric inflammatory bowel disease (IBD), but a substantial proportion of patients experience primary non-response or relapse. Tissue eosinophilia has been implicated in treatment resistance, yet its predictive value in pediatric populations remains unclear.

Methods: We conducted a retrospective nested case–control study including 80 pediatric IBD patients treated with infliximab at CHU Sainte-Justine between 2014 and 2023 Relapse cases (n = 42) were defined by an increase in the short Pediatric Crohn's Disease Activity Index (sPCDAI) ≥10, and compared with non-relapse controls (n = 38). Tissue eosinophil counts were quantified from diagnostic biopsies by blinded reviewers. Primary non-response was defined as a lack of clinical improvement before treatment change. Logistic regression and receiver operating characteristic (ROC) analyses were performed to assess associations between eosinophil counts and treatment outcomes.

Results: 80 patients were included in the study. Median age at diagnosis was 14.4 years [Q1-Q3 (first quarter – third quarter) 12.35 – 16.00]. 40 patients had a diagnosis of ulcerative colitis (UC, 50%) and the other half had a diagnosis of Crohn's disease (CD). Baseline eosinophil counts were not associated with subsequent relapse (odds ratio [OR] 1.02, 95% CI 0.98–1.06, p = 0.31), and ROC analysis demonstrated poor discrimination (AUC 0.57). In contrast, higher eosinophil counts were associated with primary non-response in ulcerative colitis patients (OR 1.08, 95% CI 1.01–1.16, p = 0.03). A cutoff of a median of ≥ 36 eosinophils per high-power field among all segments yielded 85% sensitivity and 80% specificity for predicting primary non-response (AUC 0.82).

Conclusion: Tissue eosinophil counts do not predict relapse in pediatric IBD patients treated with infliximab. However, elevated counts may identify ulcerative colitis patients at risk of primary non-response, suggesting a role for histological stratification in guiding the selection of biologics. Prospective validation in larger cohorts is warranted.

INTRODUCTION

Crohn's disease (CD) and ulcerative colitis (UC) are the two most common forms of inflammatory bowel disease (IBD), both with very high prevalence and incidence in Canada. In 2018, 230,000 people were living with IBD in Canada, of whom 130,000 had Crohn's disease. Currently, the prevalence of IBD in Canada is nearly 0.7%, or more than 1 in 150 Canadians (1). The incidence of Crohn's disease in the Canadian pediatric population is among the highest in the world, at 13.9 per 100,000 children, compared with 2–5 per 100,000 children in other regions (2, 3). Recent studies show that the incidence of pediatric IBD has tended to increase in recent years, as demonstrated by a recent study conducted at our centre between 2009 and 2019 (4).

Pediatric inflammatory bowel disease (IBD) is a chronic, relapsing condition that imposes a substantial burden on patients and health systems (5). The incidence of both Crohn's disease (CD) and ulcerative colitis (UC) has been rising worldwide, with increasing recognition in children and adolescents (6). Early and effective treatment is essential to control inflammation, prevent complications, and optimize growth and quality of life.

Among available biologics, infliximab, an anti–tumour necrosis factor alpha (TNF-α) monoclonal antibody, is a cornerstone therapy for moderate to severe pediatric IBD (6). Despite its proven efficacy, up to one-third of patients experience primary non-response during induction, and nearly half relapse during maintenance, highlighting the urgent need for reliable predictive biomarkers (7).

Eosinophils are multifunctional immune cells implicated in type 2-driven inflammation and tissue remodeling. Although traditionally associated with allergic disorders, eosinophils are increasingly recognized as contributors to the pathogenesis of IBD(8, 9). They accumulate in inflamed mucosa, release cytotoxic granule proteins, and interact with other immune cells, including T helper 2 (Th2) lymphocytes and mast cells (10, 11). Several studies have suggested that mucosal eosinophilia correlates with disease activity, particularly in UC, and may influence therapeutic response (11, 12). In adults, high eosinophil counts have been linked to treatment failure with vedolizumab and other biologics (13, 14). However, the evidence remains inconsistent, and data in children are scarce (10, 15).

Identifying histological predictors of infliximab response in pediatric IBD could improve patient stratification and guide treatment decisions. Biopsy analysis is routinely performed at diagnosis, providing an opportunity to integrate histopathology into clinical algorithms without additional burden. Yet, the predictive role of tissue eosinophil counts for infliximab outcomes in the pediatric setting has not been systematically evaluated. (16)

The present study aimed to assess whether tissue eosinophil counts at diagnosis are associated with infliximab outcomes in a pediatric IBD cohort. Specifically, we evaluated their ability to predict (1) relapse during maintenance therapy and (2) primary non-response during induction.

METHODS

Study design and population

We conducted a retrospective nested case–control study within the pediatric IBD cohort at CHU Sainte-Justine (Montreal, Canada). Patients diagnosed with colonic CD or UC between January 2000 and December 2020 were eligible if they received infliximab therapy and had diagnostic endoscopic biopsies available for review. Patients with indeterminate colitis or missing follow-up data were excluded. The study was approved by the institutional research ethics board.

Outcomes

Two outcomes were evaluated. Relapse was defined as an increase of ≥10 points in the short Pediatric Crohn's Disease Activity Index (sPCDAI) requiring clinical intervention. Primary non-response was defined as the absence of clinical improvement before treatment change during induction.

Histological assessment

Formalin-fixed paraffin-embedded biopsies obtained at diagnosis were reviewed. A pathologist and a trained investigator, blinded to clinical outcomes, quantified eosinophil counts as the peak number of eosinophils per high-power field (HPF, 400× magnification) for each segment (ileon, ascending colon, transverse colon, descending colon, sigmoid and rectum). Inter-rater reliability was excellent (intraclass correlation coefficient = 0.94) The eosinophil count per HPF was compared for all segments individually between responders and relapsing participants before using the median of all segments for further analysis.

Treatment protocol

Infliximab was administered intravenously at a standard induction regimen (10 mg/kg at weeks 0, 2, and 6), in the first 30 days following diagnosis followed by maintenance infusions every 8 weeks. Dose escalation or interval shortening was permitted at the treating physician's discretion.

Data collection
Demographic and clinical data, including age at diagnosis, sex, IBD subtype, disease location according to Paris Location, and treatment history of corticosteroids, were extracted from electronic medical records.

Statistical analysis
Baseline characteristics were compared using chi-square or Fisher's exact test for categorical variables, and Student's t-test or Wilcoxon rank-sum test for continuous variables, as appropriate. A Pearson correlation test was used to evaluate the link between circulating and epithelial eosinophil counts Logistic regression was used to assess the association between tissue eosinophil counts and outcomes, with results expressed as odds ratios (ORs) and 95% confidence intervals (CIs). Receiver operating characteristic (ROC) analysis was performed to evaluate discrimination and identify optimal cutoff values. Statistical significance was defined as $p < 0.05$. Analyses were conducted using SAS version 9.4.

RESULTS

Cohort characteristics
Eighty pediatric patients with IBD treated with infliximab were included, comprising 40 with Crohn's disease (50%) and 40 with ulcerative colitis (50%). Median age at diagnosis was 14.4 years (first quartile – third quartile [Q1-Q3] 12.35 –16.0), and 70% were male. Forty-two patients remained in remission, and 38 experienced relapses (among these 38, five patients had a primary non-response). Baseline demographic and clinical characteristics were similar between relapse and non-relapse groups (Table 1).

A Pearson correlation analysis was performed to evaluate the association between tissue eosinophil counts and blood eosinophil counts. A weak but statistically significant positive correlation was observed ($r = 0.275$, $p = 0.0141$).

Patients with ulcerative colitis had significantly higher overall eosinophil counts compared to those with Crohn's disease (median 23.6 vs. 15.5, p=0.0068). This difference was consistent across most colonic segments, including the ascending, transverse, descending, and sigmoid colon, as well as the rectum, where the largest gap was observed (29 vs. 9, p=0.0005). In contrast, the ileum showed the opposite pattern, with higher eosinophil counts in Crohn's disease (23 vs. 16.5, p=0.0364) (Table 2).

Relapse
Baseline tissue eosinophil counts did not differ significantly between patients who relapsed and those who did not (median 22,5 vs 21,75 eosinophils/HPF, $p = 0.21$). No difference was detected in the number of eosinophils between the two groups, even when stratifying the analyses for each segment individually. In logistic regression, eosinophil counts were not associated with relapse (OR 1.02, 95% CI 0.98 ; 1.06, $p = 0.23$) (Table 3). ROC analysis confirmed poor discriminatory ability (AUC 0.57; 95% CI 0.44 ; 0.71).

Primary non-response
Of the 80 patients, 5 (6,25%) met criteria for primary non-response. These patients had significantly higher mean baseline eosinophil counts compared with responders (median 40.25 vs 21.8 eosinophils/HPF, $p = 0.0139$) or non-responder (40.25 vs 21.8, p=0.0323). Circulating eosinophiles were not higher in primary non-responders (medians 0.3 vs 0.9, p=0.16).

In multivariable logistic regression adjusted for age, sex, and induction dose of infliximab, eosinophil counts were independently associated with primary non-response (OR 1.08 per eosinophil/HPF, 95% CI 1.01–1.16, $p = 0.03$).

ROC analysis identified an optimal cutoff of ≥36 eosinophils/HPF, yielding 85% sensitivity and 80% specificity (AUC 0.82; 95% CI 0.66 ; 0.97) (Figure 1).

DISCUSSION

In this retrospective cohort of pediatric IBD patients treated with infliximab, we found that tissue eosinophil counts at diagnosis were not associated with relapse during maintenance therapy. However, higher eosinophil counts were significantly associated with primary non-response in ulcerative colitis, with an optimal cutoff of ≥36 eosinophils per high-power field providing good sensitivity and specificity. These findings suggest that mucosal eosinophilia may contribute to early treatment resistance in UC, while mechanisms underlying relapse appear to be independent of eosinophil activity.

Our results align with the emerging view that eosinophils play a distinct role in the immunopathology of UC compared with Crohn's disease (17). Eosinophils accumulate preferentially in the colonic mucosa, where they release pro-inflammatory mediators such as major basic protein, eosinophil peroxidase, and cytokines including IL-5 and IL-13 (18). These factors promote epithelial barrier disruption, fibrosis, and amplification of type 2 inflammation (17, 19). It is plausible that such pathways reduce the effectiveness of TNF-α blockade, explaining the observed association with primary non-response (14). In contrast, relapse during infliximab maintenance is often driven by immunogenicity, low trough levels, or activation of TNF-independent pathways, which may account for the lack of predictive value in this setting (20).

Several adult studies support the role of eosinophils in biologic resistance. High mucosal eosinophil counts have been linked to non-response to vedolizumab in UC (13, 14), and peripheral eosinophilia has been associated with adverse outcomes in anti-TNF–treated patients (21). However, data on children are limited. Our findings contribute novel evidence from a pediatric cohort, highlighting the potential of tissue eosinophils as predictive biomarkers at treatment initiation. Importantly, the effect was observed specifically in UC, underscoring disease-specific mechanisms that merit further study.

From a clinical perspective, eosinophil quantification is a simple, inexpensive, and widely available histological measure. If validated, it could be incorporated into diagnostic pathology reports to help guide therapeutic decision-making. For instance, pediatric UC patients with high eosinophil counts at diagnosis may benefit from closer monitoring of early infliximab response, or consideration of alternative biologics such as ustekinumab or vedolizumab. Integrating histological markers with clinical and pharmacological data could ultimately improve individualized treatment strategies.

This study has some limitations. Its retrospective design and modest sample size limit generalizability, and results should be interpreted with caution. Although inter-rater reliability for eosinophil counts was excellent (ICC), histological variability remains inherent to biopsy sampling. We did not assess serum or fecal biomarkers, such as eotaxin or calprotectin, which may complement tissue eosinophilia in predictive models. Additionally, our ability to analyze subgroups was limited, particularly for Crohn's disease, as none of our primary nonresponders had Crohn's disease. Future studies should validate these findings prospectively in larger, multicenter pediatric cohorts. Integrating eosinophil counts with molecular biomarkers, pharmacokinetics, and genetic factors may yield more robust predictive algorithms. Mechanistic studies exploring the interaction between eosinophil-driven pathways and TNF blockade could also clarify therapeutic resistance. Ultimately, such research may enable precision medicine approaches, ensuring that children with IBD receive the most effective therapy from the outset.

CONCLUSION

In this pediatric IBD cohort, tissue eosinophil counts at diagnosis were not predictive of relapse during infliximab maintenance. However, higher eosinophil counts were significantly associated with primary non-response in ulcerative colitis, suggesting a role for mucosal eosinophilia in early treatment resistance. If validated, biopsy-based eosinophil quantification could serve as a simple histological biomarker to guide therapeutic stratification in pediatric UC. Prospective multicenter studies are warranted to confirm these findings and explore integration with molecular and pharmacological predictors.

TABLE 1: Distribution of demographic, clinical and histological variables in patients who maintained infliximab response.

	Total N=80	Sustained response to infliximab N=42	Relapse on infliximab requiring a change in treatment N=38	P-Value
Demographics & Baseline caracteristics				
Male sex, n (%)	39 (48.75)	19 (45.24)	20 (52.63)	0.6659
IBD type: Ulcerative colitis, n (%)	40 (50)	20 (47.62)	20 (52.63)	0.6543
Age at diagnosis, years (median [Q1-Q3])	14.40 [12.35 – 16.00]	14.35 [12.30 – 16.20]	14.45 [12.40 – 16.00]	0.9349
BMI z-score (median [Q1-Q3])	-0.630 [-1.735 – 0.500]	-0.745 [-1.920 – 0.180]	-0.560 [-1.480 – 0.780]	0.3603
Height z-score (median [Q1-Q3])	-0.120 [-0.855 – 0.600]	-0.145 [-0.970 – 0.630]	-0.075 [-0.680 – 0.450]	0.9579
Weight z-score (median [Q1-Q3])	-0.465 [-1.415 – 0.295]	-0.520 [-1.840 – 0.360]	-0.385 [-1.300 – 0.230]	0.4750
Disease Characteristics				
Crohn's disease location (Paris classification)				0.3426
Colonic (L2), n (%)	11 (27.5)	5 (22.73)	6 (33.33)	
Ileocolonic (L3), n (%)	29 (72.5)	17 (77.27)	12 (66.66)	
Localisation of Ulcerative Colitis (Paris classification)				0.3120
Proctitis (E1), n (%)	1 (2.5)	1 (5)	0 (0)	
Left-sided colitis (E2), n (%)	3 (7.5)	1 (5)	2 (10)	
Extensive colitis, distal to cecum (E3), n (%)	2 (5)	0 (0)	2 (10)	
Pancolitis (E4), n (%)	34 (85)	18 (90)	16 (80)	
UC severity at diagnosis (S0), n (%)	19 (47.5)	11 (55)	8 (40)	0.3422
Extraintestinal manifestations, n (%)	19 (48.72)	11 (52.38)	8 (44.44)	0.4075
Clinical Scores				
PUCAI score at diagnosis (median [Q1-Q3])	65.0 [55.0 – 70]	60 [52.5-70]	67.5 [55-75]	0.2079
PCDAI score at diagnosis (median [Q1-Q3])	50 [42.5 – 52.5]	47.5 [45-60]	50 [41.25-52.5]	1.0000
SES-CD score at diagnosis (median [Q1-Q3])	16.5 [12 – 23]	20 [13-25]	13.5 [9-21]	0.0893

Histology				
Architectural distortion present, n (%)	66 (82.5)	31 (73.8)	35 (92.1)	0.0357
Lymphoid follicles present, n (%)	23 (28.75)	11 (26.19)	12 (31.58)	0.5949
Granulomas present, n (%)	8 (10)	4 (9.5)	4 (10.5)	0.6040
Median eosinophil count (all sites) (median [Q1-Q3])	22.0 [15.08 – 29.17]	21.75 [13.67 – 28.0]	22.5 [15.3-34.9]	0.2128
Eosinophil count, ileum (median [Q1-Q3])	20.25 [11.5 – 34]	17.5 [9.5 – 34.0]	20.5 [16–33]	0.2699
Eosinophil count, ascending colon (median [Q1-Q3])	20.75 [12.5 – 35.25]	20.0 [12.0 – 37.5]	22 [13–33]	1.0000
Eosinophil count, transverse colon (median [Q1-Q3])	20.25 [11– 30.5]	20.25 [11.5 – 33.0]	20.25 [8.3–29.5]	0.4076
Eosinophil count, descending colon (median [Q1-Q3])	20.25 [10.5– 33.5]	19.0 [10.0 – 27.0]	24.75 [10.5–41.5]	0.3327
Eosinophil count, sigmoid colon (median [Q1-Q3])	18.5 [11.25 – 33.5]	16.5 [11.0 – 28.5]	22.5 [12.0–35.5]	0.3967
Eosinophil count, rectum (median [Q1-Q3])	16.0 [6.5 – 30.5]	14.25 [6.25 – 29.25]	16.0 [7.0–32.5]	0.5608
Laboratory Markers at Diagnosis				
C-reactive protein (mg/L) (median [Q1-Q3])	22.1 [7.2 – 47.9]	22.8 [8.9 – 72.3]	20.9 [5.4–39.4]	0.6367
Alkaline phosphatase (U/L) (median [Q1-Q3])	98 [75-120]	103 [76 – 118]	92.0 [74.0–134.0]	0.4757
ALT (U/L) (median [Q1-Q3])	10 [6-14]	10 [6 – 14]	10.0 [6.0–14.0]	0.8468
AST (U/L) (median [Q1-Q3])	15 [11-26]	28.5 [23.5 – 48]	13.5 [10.0–15.0]	0.0461
Albumin (g/L) (median [Q1-Q3])	30 [25-34]	31 [25 – 34]	30.0 [25.0–34.0]	0.7798
Fecal calprotectin (µg/g) (median [Q1-Q3])	1800 [1201-2100]	1922 [1030 – 2100]	1800 [1233–2100]	0.9917
Gamma-glutamyl transferase (U/L) (median [Q1-Q3])	13.5 [10-26]	14.5 [9.0–41.0]	12.0 [10.0–19.0]	0.4355

Hemoglobin (g/L) (median [Q1-Q3])	102 [91-115.5]	102.0 [91.0–114.0]	105.5 [92.0–118.0]	0.4372
Peripheral eosinophil count (×10⁹/L) (median [Q1-Q3])	0.3 [0.1-0.7]	0.30 [0.10–0.60]	0.20 [0.10–0.90]	0.8733
Leukocytes (×10⁹/L) (median [Q1-Q3])	10.26 [7.44-12.54]	10.12 [7.45–12.51]	10.31 [7.42–13.2]	0.7260
Variables associated to Treatments				
Delay before induction (days) (median [Q1-Q3])	-4 [-8–-2]	-4 [-8–-2]	-3.5[-8–2]	0.7207
Induction IFX dose (mg/kg) (median [Q1-Q3])	9.53 [7.89-10.20]	9.63 [8.62 – 10.53]	9.36 [5.97–10.10]	0.2319
IFX trough level during inductions (µg/mL) (median [Q1-Q3])	20.96 [11.17-29.98]	16.42 [10.27-27.66]	24.61 [14.4-37.18]	0.1462
Median Maintenance IFX dose (mg/kg) (median [Q1-Q3])	9.92 [8.74-11.32]	10.39 [9.36–11.82]	9.96 [8.70–11.60]	0.3809
Median IFX trough level during mainteantce (µg/mL) (median [Q1-Q3])	15.51 [9.67 - 20.98]	15.57 [9.67 - 20.80]	14.81 [10.4 - 24.29]	0.7679
Median anti-IFX antibody titer (AU/mL) (median [Q1-Q3])	6 [4-23]	6 [4.5-20]	6.75 [3-26.5]	1.0000
Anti-IFX antibodies >10 AU/mL, n (%),	11 (13.75)	5 (12.5)	6 (15.8)	0.7245
Low induction trough level, n (%)*	14 (17.5)	8 (20)	6 (15.8)	0.8258
Low maintenance trough level, n (%)**	10 (12.5)	4 (10)	6 (15.8)	0.3906
Number of IFX infusions, 1st year (median [Q1-Q3])	9 [6-12]	11 [10 – 13]	6 [5-8]	<.0001
Systemic corticosteroid use, n (%)	68 (85)	36 (85.71)	32 (84.21)	0.8508
Relapse & Outcomes				
Primary non-response, n (%)			5 (13)	
Treatment after relapse				
Corticosteroids, n (%)			16 (42,1)	
Tofacitinib, n (%)			4 (10.5)	

Ustekinumab, n (%)	11 (28,9)
Vedolizumab, n (%)	7 (18.4)
PUCAI score at relapse (median [Q1-Q3])	50 [40-70]
PCDAI score at relapse (median [Q1-Q3])	35 [22.5-50]
SES-CD score at relapse (median [Q1-Q3])	11 [9-24]

Tables 1 Legend * IFX trough level under 25, 15 or 10 for either the 0, 2 and 6 doses respectively.
** IFX trough level under 5

BMI : Body mass index, PUCAI: Pediatric Ulcerative Colitis Activity Index, PCDAI: Pediatric Crohn's Disease Activity Index, SES-CD: Simple Endoscopic Score – Crohn's Disease , IFX, Infliximab

TABLE 2: Comparison of eosinophil counts by intestinal segment in UC and CD patients

	Patients with UC N=40	Patients with CD N=40	P-value
Median eosinophil count (all sites) (median [Q1-Q3])	23.62[15.75– 35.12]	15.5 [9.75-23.75]	0.0068
Eosinophil count, ileum (median [Q1-Q3])	16.5[9.5 –24.5]	23 [17–40]	0.0364
Eosinophil count, ascending colon (median [Q1-Q3])	23.5 [15.0 – 37.5]	18.5 [8–31.5]	0.0469
Eosinophil count, transverse colon (median [Q1-Q3])	26 [16 – 35.5]	15.5 [8.5–22.5]	0.0085
Eosinophil count, descending colon (median [Q1-Q3])	25 [13.5 – 43.0]	15.5 [8–29.5]	0.0309
Eosinophil count, sigmoid colon (median [Q1-Q3])	26.5 [14.5 – 40]	14 [8.5–24.5]	0.0079
Eosinophil count, rectum (median [Q1-Q3])	29[14 – 35.5]	9 [5.5–16]	0.0005

TABLE 3: Binary logistic regression for the variables independently associated with a relapse to infliximab treatment necessitating the addition of a new treatment.

	Univariate Odds Ratio		Adjusted Odds Ratio	
	OR (95% CI)	**P-Value**	**OR (95% CI)**	**P-Value**
Age at diagnosis, years	1.02 (0.92 ; 1.12)	0.7817	0.98 (0.81 ; 1.20)	0.8553
Sex (female vs male)	0.74 (0.31 ; 1.79)	0.5092	0.78 (0.30 ; 1.99)	0.5969
IBD type (CU vs CD)	1.22 (0.51 ; 2.94)	0.6545	1.43 (0.51 ; 1.01)	0.4987

	Univariate Odds Ratio		Adjusted Odds Ratio	
	OR (95% CI)	**P-Value**	**OR (95% CI)**	**P-Value**
Median eosinophil count (all sites)	0.87 (0.74 ; 1.03)	0.2078	1.02 (0.99 ; 1.06)	0.2260
Induction dose of infliximab mg/kg	0.741 (0.55 ; 0.991)	0.0350	0.782 (0.60 ; 1.01)	0.0628

TABLE 4: Binary logistic regression for the variables independently associated with a primary non-response to infliximab in CU patients.

	Univariate Odds Ratio		Adjusted Odds Ratio	
	OR (95% CI)	**P-Value**	**ORa (95% CI)**	**P-Value**
Age at diagnosis, years	1.20 (0.78 ; 1.87))	0.4075	1.04 (0.57 ; 1.9)	0.5722
Sex (female vs male)	0.22 (0.02 ; 2.05)	0.1831	0.21 (0.01 ; 3.16)	0.1846
Median eosinophil count (all sites)	1.08 (1.02 ; 1.14)	0.0089	1.08 (1 ; 1.16)	0.0199
Induction dose of infliximab mg/kg	0.99 (0.62 ; 1.57)	0.1855	0.66 (0.34 ; 1.27)	0.5997

FIGURE 1: Receiver operating characteristic (ROC) curve for baseline eosinophil counts predicting primary non-response in ulcerative colitis.



REFERENCES

1. Coward S, Benchimol EI, Kuenzig ME, Windsor JW, Bernstein CN, Bitton A, et al. The 2023 Impact of Inflammatory Bowel Disease in Canada: Epidemiology of IBD. J Can Assoc Gastroenterol. 2023;6(Suppl 2):S9-s15.
2. Sýkora J, Pomahačová R, Kreslová M, Cvalínová D, Štych P, Schwarz J. Current global trends in the incidence of pediatric-onset inflammatory bowel disease. World J Gastroenterol. 2018;24(25):2741-63.
3. Rocchi A, Benchimol EI, Bernstein CN, Bitton A, Feagan B, Panaccione R, et al. Inflammatory bowel disease: a Canadian burden of illness review. Can J Gastroenterol. 2012;26(11):811-7.
4. Sassine S, Djani L, Cambron-Asselin C, Savoie M, Lin YF, Qaddouri M, et al. Risk Factors of Clinical Relapses in Pediatric Luminal Crohn's Disease: A Retrospective Cohort Study. Am J Gastroenterol. 2022;117(4):637-46.
5. Marsal J, Barreiro-de Acosta M, Blumenstein I, Cappello M, Bazin T, Sebastian S. Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Frontiers in Medicine. 2022;Volume 9 - 2022.
6. Tsumura N, Kato K, Yasuda R, Yoshioka S, Takedatsu H, Mizuochi T. Long-Term Response Durability of Infliximab for Pediatric Inflammatory Bowel Disease in Japan: A Single Center Experience. Pediatr Gastroenterol Hepatol Nutr. 2025;28(3):166-75.
7. Lecoutour A, Dupont C, Caldari D, Dumant C, Vanrenterghem A, Ruiz M, et al. Efficacy of infliximab after loss of response of/intolerance to adalimumab in pediatric Crohn's disease: A retrospective multicenter cohort study of the “GETAID pédiatrique”. Journal of Pediatric Gastroenterology and Nutrition. 2024;78(5):1116-25.
8. Tomii T, Kano G. Eosinophils in inflammatory bowel disease pathogenesis: an ROS-centric view. Front Allergy. 2025;6:1608202.

9. Hogan SP. Functional role of eosinophils in gastrointestinal inflammation. Immunol Allergy Clin North Am. 2009;29(1):129-40, xi.
10. Mehta P, Furuta GT. Eosinophils in Gastrointestinal Disorders: Eosinophilic Gastrointestinal Diseases, Celiac Disease, Inflammatory Bowel Diseases, and Parasitic Infections. Immunol Allergy Clin North Am. 2015;35(3):413-37.
11. Alhmoud T, Gremida A, Colom Steele D, Fallahi I, Tuqan W, Nandy N, et al. Outcomes of inflammatory bowel disease in patients with eosinophil-predominant colonic inflammation. BMJ Open Gastroenterol. 2020;7(1):e000373.
12. Morgenstern S, Brook E, Rinawi F, Shamir R, Assa A. Tissue and peripheral eosinophilia as predictors for disease outcome in children with ulcerative colitis. Dig Liver Dis. 2017;49(2):170-4.
13. Gabriëls RY, Bourgonje AR, von Martels JZH, Blokzijl T, Weersma RK, Galinsky K, et al. Mucosal Eosinophil Abundance in Non-Inflamed Colonic Tissue Is Associated with Response to Vedolizumab Induction Therapy in Inflammatory Bowel Disease. J Clin Med. 2022;11(14).
14. Kim EM, Randall C, Betancourt R, Keene S, Lilly A, Fowler M, et al. Mucosal Eosinophilia Is an Independent Predictor of Vedolizumab Efficacy in Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2020;26(8):1232-8.
15. Zahmatkesh A, Sohouli MH, Zojaji R, Aghdam MK, Rohani P. Effect of Tissue Eosinophilia on the Disease Outcome of Pediatric With Inflammatory Bowel Disease (IBD). JGH Open. 2025;9(5):e70187.
16. Colman RJ, Dhaliwal J, Rosen MJ. Predicting Therapeutic Response in Pediatric Ulcerative Colitis-A Journey Towards Precision Medicine. Front Pediatr. 2021;9:634739.
17. Jacobs I, Ceulemans M, Wauters L, Breynaert C, Vermeire S, Verstockt B, et al. Role of Eosinophils in Intestinal Inflammation and Fibrosis in Inflammatory Bowel Disease: An Overlooked Villain? Front Immunol. 2021;12:754413.
18. Salvo-Romero E, Rodiño-Janeiro BK, Albert-Bayo M, Lobo B, Santos J, Farré R, et al. Eosinophils in the Gastrointestinal Tract: Key Contributors to Neuro-Immune Crosstalk and Potential Implications in Disorders of Brain-Gut Interaction. Cells. 2022;11(10):1644.
19. Furuta GT, Nieuwenhuis EES, Karhausen J, Gleich G, Blumberg RS, Lee JJ, et al. Eosinophils alter colonic epithelial barrier function: role for major basic protein. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2005;289(5):G890-G7.
20. Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, et al. Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease. Gastroenterology. 2015;148(7):1320-9.e3.
21. Click B, Anderson AM, Koutroubakis IE, Rivers CR, Babichenko D, Machicado JD, et al. Peripheral Eosinophilia in Patients With Inflammatory Bowel Disease Defines an Aggressive Disease Phenotype. Am J Gastroenterol. 2017;112(12):1849-58.